Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Dienstag 9. Dezember 2025: Die Lesesäle der Deutschen Nationalbibliothek in Leipzig öffnen wegen einer Personalversammlung erst ab 13 Uhr. // Tuesday 9 December 2025: The reading rooms of the German National Library in Leipzig will open at 13:00 due to a staff assembly.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

31 - 40 von 129

	31	Biosimilars in der Kinderrheumatologie Enthalten in Kinder- und Jugendmedizin Bd. 21, 2021, Nr. 05: 339-348
	32	Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review Enthalten in BioDrugs 6.12.2021: 1-13
	33	The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review Enthalten in Advances in therapy 15.11.2021: 1-33
	34	Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany Enthalten in Inflammatory intestinal diseases Bd. 6, 2021, Nr. 1: 48-60
	35	Joint imaging platform for federated clinical data analytics Scherer, Jonas. - Freiburg : Universität, 2020
	36	Was tut ein Geschichtsschreiber? Enthalten in Philologus Bd. 164, 2020, Nr. 2: 250-2689. 19 S.
	37	Online validation of combined mood induction procedures Marcusson-Clavertz, David. - Ludwig-Maximilians-Universität München, 2019
	38	How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity Enthalten in Biotechnology journal Bd. 14, 2019, Nr. 4. 9 S.
	39	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting Enthalten in BioDrugs 3.4.2019: 1-13
	40	Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting Enthalten in BioDrugs 3.4.2019: 1-8